clinical trial · NCT05978401
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Guangzhou Gloria Biosciences Co., Ltd.·phase2·unknown·n = 152
Advanced Non-Small Cell Lung CancerGLS-012+GLS-010GLS-012+GLS-010GLS-012+GLS-010+pemetrexed+carboplatinGLS-012+GLS-010+paclitaxel+carboplatin
brief summary
This is a multicenter, open Phase I/II study. The trial consists of two parts, Part1 is a dose-escalation/expansion study, Part2 is a combination of GLS-010 and GLS-010+GLS-012 with standard chemotherapy for advanced non-small-cell lung cancer respectively to assess preliminary efficacy at the combination dose.
started
Aug 10, 2023
primary completion
Apr 1, 2025
completion
Apr 1, 2026
last updated
Aug 7, 2023
official title
A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer (Triumph-02)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol